Sign in
4

Changes in Ownership

Enliven Therapeutics, Inc. Filed Acc 0001415889-25-009301

CHIEF FINANCIAL OFFICER sold 3,250 shares at $21.33 ($69,321)

  • CHIEF FINANCIAL OFFICER acquired 3,250 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Hohl Benjamin · CHIEF FINANCIAL OFFICER

Table I: Non-derivative

2 lines
Date Transaction Shares Price Value Owned after D/I
2025-03-27 Exercise or conversion : show line 1 in the form 10b5-1 +3,250 $2.48 $8,060 26,250 D
2025-03-27 Sale : show line 2 in the form 10b5-1 −3,250 $21.33 $69,321 23,000 D
Open-market sales · 3,250 sh · avg $21.33 · $69,321

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2025-03-27 Exercise or conversion : show line 3 in the form 10b5-1 Stock Option (right to buy) −3,250 128,556 D
Loading xslF345X05/form4-03312025_110331.xml…